Avons-nous les moyens financiers pour l'immunothérapie ?

In France, some simulations showed that the cost of the drugs could change in a ratio of 1 to 13 between pembrolizumab and docetaxel, 1 to 3.5 with pemetrexed. Ratios are inferior with nivolumab. We need for new medico-economical studies, particularly with immunotherapy, to confirm that to prescribe the right drug to the right patient could be cost-effective.